Lifestyle Advice Combined with Personalized Estimates of Genetic or Phenotypic Risk of Type 2 Diabetes, and Objectively Measured Physical Activity: A Randomized Controlled Trial

Job G Godino, Esther M F van Sluijs, Theresa M Marteau, Stephen Sutton, Stephen J Sharp, Simon J Griffin, Job G Godino, Esther M F van Sluijs, Theresa M Marteau, Stephen Sutton, Stephen J Sharp, Simon J Griffin

Abstract

Background: Information about genetic and phenotypic risk of type 2 diabetes is now widely available and is being incorporated into disease prevention programs. Whether such information motivates behavior change or has adverse effects is uncertain. We examined the effect of communicating an estimate of genetic or phenotypic risk of type 2 diabetes in a parallel group, open, randomized controlled trial.

Methods and findings: We recruited 569 healthy middle-aged adults from the Fenland Study, an ongoing population-based, observational study in the east of England (Cambridgeshire, UK). We used a computer-generated random list to assign participants in blocks of six to receive either standard lifestyle advice alone (control group, n = 190) or in combination with a genetic (n = 189) or a phenotypic (n = 190) risk estimate for type 2 diabetes (intervention groups). After 8 wk, we measured the primary outcome, objectively measured physical activity (kJ/kg/day), and also measured several secondary outcomes (including self-reported diet, self-reported weight, worry, anxiety, and perceived risk). The study was powered to detect a between-group difference of 4.1 kJ/kg/d at follow-up. 557 (98%) participants completed the trial. There were no significant intervention effects on physical activity (difference in adjusted mean change from baseline: genetic risk group versus control group 0.85 kJ/kg/d (95% CI -2.07 to 3.77, p = 0.57); phenotypic risk group versus control group 1.32 (95% CI -1.61 to 4.25, p = 0.38); and genetic risk group versus phenotypic risk group -0.47 (95% CI -3.40 to 2.46, p = 0.75). No significant differences in self-reported diet, self-reported weight, worry, and anxiety were observed between trial groups. Estimates of perceived risk were significantly more accurate among those who received risk information than among those who did not. Key limitations include the recruitment of a sample that may not be representative of the UK population, use of self-reported secondary outcome measures, and a short follow-up period.

Conclusions: In this study, we did not observe short-term changes in behavior associated with the communication of an estimate of genetic or phenotypic risk of type 2 diabetes. We also did not observe changes in worry or anxiety in the study population. Additional research is needed to investigate the conditions under which risk information might enhance preventive strategies. (Current Controlled Trials ISRCTN09650496; Date applied: April 4, 2011; Date assigned: June 10, 2011).

Trial registration: The trial is registered with Current Controlled Trials, ISRCTN09650496.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Flow of participants through the…
Fig 1. Flow of participants through the DRCT.
Baseline characteristics were similar among the three study groups (Table 1). There were slightly more female (52.9%) than male participants. The mean (SD) age at which participants finished full-time education was 19.4 (4.4) y and most were employed full-time (68.0%). Overall, 10.6% were current smokers, and 26.8% consumed more than 11 units of alcohol per wk. Few participants were prescribed steroid or antihypertensive medication (5.8%) or had a positive family history for diabetes (23.0%). On average, participants were overweight (mean [SD] body mass index of 26.1 [4.2] kg/m2), but their HbA1c level was in the normal range (mean [SD] of 36.3 [4.4] mmol/mol).
Fig 2. Intervention effects on the primary…
Fig 2. Intervention effects on the primary outcome: physical activity.
Physical activity was defined as physical activity energy expenditure (kJ/kg/d) measured with a combined heart rate monitor and accelerometer. Plus–minus values are means ± standard error (SE). Analysis of covariance was used to assess differences between groups at follow-up, adjusted for baseline.

References

    1. Hu FB. Globalization of diabetes: The role of diet, lifestyle, and genes. Diabetes Care. 2011;34: 1249–57. 10.2337/dc11-0442
    1. Simmons RK, Unwin N, Griffin SJ. International Diabetes Federation: An update of the evidence concerning the prevention of type 2 diabetes. Diabetes Res Clin Pract. 2010;87: 143–149. 10.1016/j.diabres.2009.10.003
    1. Ahmad LA, Crandall JP. Type 2 diabetes prevention: A review. Clin Diabetes. 2010;28: 53–59. 10.2337/diaclin.28.2.53
    1. Yates T, Davies M, Khunti K. Preventing type 2 diabetes: can we make the evidence work? Postgrad Med J. 2009;85: 475–80. 10.1136/pgmj.2008.076166
    1. Edelman E, Eng C. A practical guide to interpretation and clinical application of personal genomic screening. BMJ. 2009;339: b4253 10.1136/bmj.b4253
    1. Mihaescu R, Meigs J, Sijbrands E, Janssens AC. Genetic risk profiling for prediction of type 2 diabetes. PLOS Curr. 2011;3: RRN1208 10.1371/currents.RRN1208
    1. McBride CM, Koehly LM, Sanderson SC, Kaphingst KA. The behavioral response to personalized genetic information: Will genetic risk profiles motivate individuals and families to choose more healthful behaviors? Annu Rev Public Health. 2010;31: 89–103. 10.1146/annurev.publhealth.012809.103532
    1. Wang C, Bowen DJ, Kardia SLR. Research and practice opportunities at the intersection of health education, health behavior, and genomics. Heal Educ Behav. 2005;32: 686–701. 10.1177/1090198105278827
    1. Loos RJF. Genetics: Genome-wide risk profiles—will they change your life(style)? Nat Rev Endocrinol. Nature Publishing Group; 2011;7: 252–4. 10.1038/nrendo.2011.41
    1. Marteau TM, Weinman J. Self-regulation and the behavioural response to DNA risk information: A theoretical analysis and framework for future research. Soc Sci Med. 2006;62: 1360–8. 10.1016/j.socscimed.2005.08.005
    1. Marteau TM. Genetic risk and behavioural change. BMJ. 2001;322: 1056–1059. 10.1136/bmj.322.7293.1056
    1. Bensend TA, Veach PMC, Niendorf KB. What’s the harm? Genetic counselor perceptions of adverse effects of genetics service provision by non-genetics professionals. J Genet Couns. 2014;23: 48–63. 10.1007/s10897-013-9605-3
    1. Collins RE, Wright AJ, Marteau TM. Impact of communicating personalized genetic risk information on perceived control over the risk: A systematic review. Genet Med. 2011;13: 273–7. 10.1097/GIM.0b013e3181f710ca
    1. Cameron LD, Sherman KA, Marteau TM, Brown PM. Impact of genetic risk information and type of disease on perceived risk, anticipated affect, and expected consequences of genetic tests. Heal Psychol. 2009;28: 307–16. 10.1037/a0013947
    1. Milne S, Sheeran P, Orbell S. Prediction and Intervention in Health-Related Behavior: A Meta-Analytic Review of Protection Motivation Theory. J Appl Soc Psychol. 2000;30: 106–143. 10.1111/j.1559-1816.2000.tb02308.x
    1. McClure J. Are biomarkers useful treatment aids for promoting health behavior change? An empirical review. Am J Prev Med. 2002;22: 200–207. 10.1016/S0749-3797(01)00425-1
    1. Hollands GJ, French DP, Griffin SJ, Prevost AT, Sutton S, King S, et al. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. Bmj. 2016;352: i1102 10.1136/bmj.i1102
    1. Voils CI, Coffman CJ, Grubber JM, Edelman D, Sadeghpour A, Maciejewski ML, et al. Does Type 2 Diabetes Genetic Testing and Counseling Reduce Modifiable Risk Factors? A Randomized Controlled Trial of Veterans. J Gen Intern Med. 2015;30: 1591–8. 10.1007/s11606-015-3315-5
    1. Grant RW, O’Brien KE, Waxler JL, Vassy JL, Delahanty LM, Bissett LG, et al. Personalized genetic risk counseling to motivate diabetes prevention: a randomized trial. Diabetes Care. 2013;36: 13–9. 10.2337/dc12-0884
    1. Godino JG, van Sluijs EMF, Marteau TM, Sutton S, Sharp SJ, Griffin SJ. Effect of communicating genetic and phenotypic risk for type 2 diabetes in combination with lifestyle advice on objectively measured physical activity: protocol of a randomised controlled trial. BMC Public Health. BMC Public Health; 2012;12: 444 10.1186/1471-2458-12-444
    1. MRC Epidemiology Unit. The Fenland Study. In: 2007 [Internet]. [cited 1 Nov 2011]. Available:
    1. Brage S, Brage N, Franks PW, Ekelund U, Wareham NJ. Reliability and validity of the combined heart rate and movement sensor Actiheart. Eur J Clin Nutr. 2005;59: 561–70. 10.1038/sj.ejcn.1602118
    1. Cardiovascular Review Group Committee on Medical Aspects of Food Policy. Nutritional aspects of cardiovascular disease. Report on health and social subjects 46. London; 1994.
    1. Department of Health Physical Activity Health Improvement and Prevention. At least five a week: Evidence on the impact of physical activity and its relationship to health. A report from the Chief Medical Officer. London; 2004 Dec.
    1. Price H. Risk communication: Why, what and how? Diabetes Prim Care. 2010;12: 100–104.
    1. Gigerenzer G, Edwards A. Simple tools for understanding risks: From innumeracy to insight. BMJ. 2003;327: 741–744. 10.1136/bmj.327.7417.741
    1. Edwards A, Gray J, Clarke A, Dundon J, Elwyn G, Gaff C, et al. Interventions to improve risk communication in clinical genetics: Systematic review. Patient Educ Couns. 2008;71: 4–25. 10.1016/j.pec.2007.11.026
    1. Fagerlin A, Zikmund-Fisher BJ, Ubel PA. “If I’m better than average, then I’m ok?”: Comparative information influences beliefs about risk and benefits. Patient Educ Couns. 2007;69: 140–144. 10.1016/j.pec.2007.08.008
    1. Mason D, Prevost AT, Sutton S. Perceptions of absolute versus relative differences between personal and comparison health risk. Heal Psychol. 2008;27: 87–92. 10.1037/0278-6133.27.1.87
    1. Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. BMJ. 2002;324: 827–30. 10.1136/bmj.324.7341.827
    1. Cameron L. Can our health behaviour models handle imagery-based processes and communications? Eur Heal Psychol. 2009;11: 56–58.
    1. DeCODEme. Risk calculations. Reykjavík, Iceland; 2007.
    1. Navigenics. The science behind the Navigenics service. Forster City, California; 2007.
    1. 23andMe. (White Paper 23–01) Estimating genotype-specific incidence for one or several loci. Mountain View, California; 2007.
    1. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: Towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev. 2000;16: 164–71.
    1. Rahman M, Simmons RK, Harding A-H, Wareham NJ, Griffin SJ. A simple risk score identifies individuals at high risk of developing type 2 diabetes: A prospective cohort study. Fam Pract. 2008;25: 191–6. 10.1093/fampra/cmn024
    1. Brage S, Ekelund U, Brage N, Hennings M a, Froberg K, Franks PW, et al. Hierarchy of individual calibration levels for heart rate and accelerometry to measure physical activity. J Appl Physiol. 2007;103: 682–92. 10.1152/japplphysiol.00092.2006
    1. Brage S, Brage N, Franks PW, Ekelund U, Wong M-Y, Andersen LB, et al. Branched equation modeling of simultaneous accelerometry and heart rate monitoring improves estimate of directly measured physical activity energy expenditure. J Appl Physiol. 2004;96: 343–51. 10.1152/japplphysiol.00703.2003
    1. Thompson D, Batterham AM, Bock S, Robson C, Stokes K. Assessment of low-to-moderate intensity physical activity thermogenesis in young adults using synchronized heart rate and accelerometry with branched-equation modeling. J Nutr. 2006;136: 1037–42.
    1. Strath SJ, Brage S, Ekelund U. Integration of physiological and accelerometer data to improve physical activity assessment. Med Sci Sport Exerc. 2005;37: S563–S571. 10.1249/01.mss.0000185650.68232.3f
    1. StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP; 2011.
    1. White IR, Thompson SG. Adjusting for partially missing baseline measurements in randomized trials. Stat Med. 2005;24: 993–1007. 10.1002/sim.1981
    1. Godino JG, Watkinson C, Corder K, Marteau TM, Sutton S, Sharp SJ, et al. Impact of personalised feedback about physical activity on change in objectively measured physical activity (the FAB Study): A randomised controlled trial. Baradaran HR, editor. PLoS One. Public Library of Science; 2013;8: e75398 10.1371/journal.pone.0075398
    1. Borm GF, Fransen J, Lemmens W a JG. A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol. 2007;60: 1234–8. 10.1016/j.jclinepi.2007.02.006
    1. Zlowodzki M, Bhandari M. Outcome measures and implications for sample-size calculations. J Bone Jt Surg. 2009;91 Suppl 3: 35–40. 10.2106/JBJS.H.01602
    1. Godino JG, van Sluijs EMF, Sutton S, Griffin SJ. Understanding perceived risk of type 2 diabetes in healthy middle-aged adults: A cross-sectional study of associations with modelled risk, clinical risk factors, and psychological factors. Diabetes Res Clin Pract. 2014;106: 412–419. 10.1016/j.diabres.2014.10.004
    1. Marteau TM, French DP, Griffin SJ, Prevost AT, Sutton S, Watkinson C, et al. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. Cochrane Database Syst Rev. 2010;10: CD007275 10.1002/14651858.CD007275.pub2
    1. Bloss CS, Schork NJ, Topol EJ. Effect of Direct-to-Consumer Genomewide Profiling to Assess Disease Risk. N Engl J Med. 2011;364: 524–534. 10.1056/NEJMoa1011893
    1. Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med. 2008;10: 19–32. 10.1097/GIM.0b013e31815f524f
    1. Usher-Smith JA, Silarova B, Schuit E, Moons KGM, Griffin SJ. Impact of provision of cardiovascular disease risk estimates to healthcare professionals and patients: a systematic review. BMJ Open. 2015;5: e008717 10.1136/bmjopen-2015-008717
    1. Kullo IJ, Jouni H, Austin EE, Brown S-A, Kruisselbrink TM, Isseh IN, et al. Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial). Circulation. 2016;133: 1181–8. 10.1161/CIRCULATIONAHA.115.020109
    1. Sivell S, Elwyn G, Gaff CL, Clarke AJ, Iredale R, Shaw C, et al. How risk is perceived, constructed and interpreted by clients in clinical genetics, and the effects on decision making: Systematic review. J Genet Couns. 2008;17: 30–63. 10.1007/s10897-007-9132-1
    1. Frieden TR. A framework for public health action: The health impact pyramid. Am J Public Health. 2010;100: 590–5. 10.2105/AJPH.2009.185652

Source: PubMed

3
Tilaa